We used two constructs with potential applicability in CLL: an anti-CD19 CAR sequence containing 4-1BB and CD3ζ and a CAR sequence against the CLL neoantigen IGLV3-21R110 containing the same elements (Figure 1A). The gene discussed is CD247; the disease is B-cell chronic lymphocytic leukemia.